Focus on hepatitis. HCV protease inhibitor does well in early clinical trial.
Carter
Michael
M
D000998:Antiviral Agents / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D006526:Hepatitis C / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D010447:Peptide Hydrolases / Q000187:drug effects*; D010919:Placebos; D011480:Protease Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010919:Placebos; D011480:Protease Inhibitors; D011994:Recombinant Proteins; D010447:Peptide Hydrolases